This study tests a new asthma medicine, AZD8630, given through a special inhaler. It's for adults with serious asthma not well controlled by their current inhalers. The study checks how safe and effective AZD8630 is, using different doses. It lasts up to 57 weeks, with a main treatment phase up to 52 weeks. Around 516 participants will join from 20 to 25 countries.

To qualify, you must be 18 to 80 years old, have had asthma for at least a year, and a history of asthma flare-ups in the past year. You can't join if you have other serious lung diseases, recent asthma treatment, or certain heart problems. Also, participants must use effective birth control during the study.

• Study duration: up to 57 weeks.
• Conducted in 220 centers worldwide.
• Requires commitment to regular visits and tests.

Joining helps understand how well AZD8630 works, but there are risks, like any new treatment. Discuss with your doctor if joining is right for you.